Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.
about
Tumor necrosis factor-alpha antibody for induction of remission in Crohn's diseaseTumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel diseasePreliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case reportAnti-TNF therapy for juvenile idiopathic arthritis-related uveitisBiologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsStructural Basis for Treating Tumor Necrosis Factor (TNF )-associated Diseases with the Therapeutic Antibody InfliximabAn indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitisThalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's diseaseDifferences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissueGenome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritisAnti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort StudyTreatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's diseaseMolecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapiesAntitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in AsiaSummary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatmentHumanization and characterization of an anti-human TNF-α murine monoclonal antibody.Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease.Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.The safety of infliximab infusions in the community settingDifferent tumor necrosis factor α antagonists have different effects on host susceptibility to disseminated and oropharyngeal candidiasis in mice.Anti-TNF agents in Crohn's disease.Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.Recent advances in inflammatory bowel disease.Cytokine modulators in the treatment of sarcoidosis.Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up.TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.Pharmacotherapy for uveitis: current management and emerging therapy.Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives.Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment.Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size.Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.Clinically useful monoclonal antibodies in treatment.Alterations in the function of circulating mononuclear cells derived from patients with Crohn's disease treated with mastic.Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.Infliximab in the treatment of plaque type psoriasis.New biologics in the management of Crohn's disease: focus on certolizumab pegol.Infliximab therapy in pediatric Crohn's disease: a review.
P2860
Q24247745-31EBB92E-A1C1-4B80-8CE1-A65538F882ACQ24669999-AA89456A-F57C-46C4-9AEB-CF642273CB94Q24675216-587DCCFE-D801-4C28-8A80-B50933E18CE8Q24799647-A9481712-967A-4056-9FA2-E59958BDABFFQ26849811-600FB7EC-C4DB-4A2F-884E-9D6D2D2F2CCEQ26999078-EE3F8D08-386D-48E1-9E99-CE0F16FDDD0AQ27676857-5C879743-2D6A-4FAE-8BC3-3717A6F3E4A5Q28079322-A1E7A99A-7D5D-49DB-81F8-9ECDD883F39FQ28344943-1C6A2E28-259D-41FE-9735-0262612D949AQ28469340-BF7F9C88-4CA7-4649-983D-097EF9930763Q28489093-7C0A27CB-ACAB-4C87-94EE-401EA7BA9B09Q28553954-4FDD9939-96F4-4AB8-B0EF-E9322EE52E34Q33617966-19B6A36B-6841-482B-B3A9-538155EA345CQ33629320-BAFE38A3-B344-4889-B89D-5EAF9997B195Q33641577-81202A7D-0907-4A5F-895E-3AFD128CB09BQ33667789-21AAEB03-DF3E-40BA-8400-8C555442E3DCQ33782349-58E00246-52F7-456F-ADF9-9F6D71C9E47EQ33815758-BA490ED9-A12C-4315-A7B3-AA1E16E3AB48Q33904308-07801DF1-E29A-4AA8-8551-CB1288B8DD21Q33915940-61BCDBC4-7809-4065-9723-7FFE34EEB918Q33916750-3BEDC6E2-CF62-4A5C-BC0D-4E300902063DQ33927362-E8EF2529-82AB-4BBF-BC68-BBA6FD951978Q34074674-56D830BF-F357-44F6-AFED-C2F814DA4C45Q34127277-FA199079-F090-4D5F-9F87-A63951883F56Q34188405-2464F0C0-C7E0-4C0F-8F79-8581978704ADQ34190083-97249FE6-6DA0-489C-B5EF-99D7B0763760Q34225622-B09211BE-CAED-471D-B04B-5B44C0FC53CCQ34240744-8E0D1C57-93BB-40E3-B3C2-FF2B894799ACQ34256006-40AA98F2-9926-4321-9BB8-263240837F20Q34274075-B92E3670-5DEB-4F1C-BB3D-BF4C93E0650DQ34316206-249218A2-F5C3-41B1-896E-3CC949429FC0Q34319316-839994CC-11A2-43F9-B77B-EF3819C64969Q34445142-BC6B4A7A-027D-4FF7-AD5A-306A2CB9727FQ34528217-FAEA3514-AEDC-45A8-9590-C0EEB3FED173Q34543634-C02DB808-5DED-4781-8098-8323CBA1F111Q34606228-0ECA04AE-18C8-449A-9FE4-A4C5386B1E8AQ34614211-9CA5698D-D380-4E9F-952E-8C22109D9202Q34620291-3165B248-4093-40C3-ACD3-E1491B11DC93Q35026264-CDA5EC55-A3A2-4875-A515-52FED8E0B68CQ35026358-381C6D50-3E4D-404B-8147-7B75E76EF9EA
P2860
Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Chimeric anti-TNF-alpha monocl ...... tes immune effector functions.
@en
type
label
Chimeric anti-TNF-alpha monocl ...... tes immune effector functions.
@en
prefLabel
Chimeric anti-TNF-alpha monocl ...... tes immune effector functions.
@en
P2093
P921
P356
P1433
P1476
Chimeric anti-TNF-alpha monocl ...... tes immune effector functions.
@en
P2093
P304
P356
10.1006/CYTO.1995.0029
P577
1995-04-01T00:00:00Z